LONDON-- Late last month, partners Eli Lilly and Boehringer Ingelheim announced that their SGLT2 diabetes med, Jardiance, had gone where no others had gone before. While its rivals had always either increased the risk of cardiovascular events or, at best, had no effect, the newcomer showed it could actually lower the risk of heart attack, stroke and death from cardiovascular causes.
Back in June, researchers unveiled details of the ELIXA trial, which put Sanofi's Lyxumia in the clear as far as cardiovascular safety risks go. Now, a new analysis of the study shows that in Type 2 patients with acute coronary syndrome, the diabetes med didn't increase the rate of cardiovascular events--but it didn't decrease it, either.
The good news keeps rolling in for Merck when it comes to the cardiovascular safety of its DPP-4 inhibitor, Januvia. According to a new analysis of the TECOS trial, patients with Type 2 diabetes and cardiovascular disease--even those with a history of heart failure--can take the drug without an increased risk of CV complications.
Denmark's Novo Nordisk has filling, packaging and a device manufacturing in the U.S., but when it comes to its insulin API production, it has kept that close to home. But CEO Lars Rebien Sørensen says it looks like it might be time to open its first plant in the U.S.
Sanofi is expanding its relationship with close partner Evotec, signing a deal worth up to $330 million to collaborate on cell-replacement therapies for diabetes.
The mystery of Ron Evans' new biotech startup has been solved. Armed with $36 million in cash from A-list venture investors and backed by a pro team recruited from Rich Heyman's Aragon/Seragon starring cancer drug startups, the prominent Salk investigator and his old buddy Heyman are coming out of stealth mode today with a new company called Metacrine.
Olivier Brandicourt, CEO of Sanofi, gave his thoughts on the July 30 earnings call about trying to launch a simplification program in the midst of high-profile global rollouts, competition and dealmaking. He also picked one contest to watch in Japan that may be a good gauge of the company's performance on all counts.
A meta-analysis of data from more than 160,000 diabetics has offered some convincing data to support the theory that PPARγ activation by glitazones--either Avandia (GlaxoSmithKline's rosiglitazone) or pioglitazone--offers significant protection against Parkinson's disease. And the researchers who did the study say that their work should help accelerate work in the field.
Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug--a key part of the pipeline--slashed HbA1c levels by 1.5% and 1.6%.
Israel's Oramed announced final-stage talks of a $50 million deal to sell China rights for its clinical-stage oral insulin candidate to a consortium of investors. The group consists of Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development.